The epidemiology of Huntington disease in British Columbia

Introduction: Global prevalence estimates for Huntington Disease (HD) vary widely, and those cited for Canada are outdated and not specific to British Columbia (BC). The most recent incidence calculation was performed in BC and includes diagnoses only up to the year 1999. Reports on the population...

Full description

Bibliographic Details
Main Author: Fisher, Emily Rachel
Language:English
Published: University of British Columbia 2012
Online Access:http://hdl.handle.net/2429/43319
id ndltd-UBC-oai-circle.library.ubc.ca-2429-43319
record_format oai_dc
spelling ndltd-UBC-oai-circle.library.ubc.ca-2429-433192018-01-05T17:26:06Z The epidemiology of Huntington disease in British Columbia Fisher, Emily Rachel Introduction: Global prevalence estimates for Huntington Disease (HD) vary widely, and those cited for Canada are outdated and not specific to British Columbia (BC). The most recent incidence calculation was performed in BC and includes diagnoses only up to the year 1999. Reports on the population at risk in Canada are based on theories and estimates that do not pertain to any particular population. Despite the presence of an extensive laboratory and clinical research hub in this province, a comprehensive epidemiological study of the prevalence, incidence and population at risk for HD has never been assessed. As such, the specific objectives of this study were to: 1) Calculate the minimum prevalence of HD in BC on April 1, 2012; 2) Calculate the incidence of HD in BC from January 1, 2001- December 31, 2011; and 3) Calculate the minimum population at risk for HD in BC on April 1, 2012. Methods: A comprehensive province-wide assessment of the HD patient population and the population at risk was conducted using multiple sources of ascertainment including: UBC HD clinic records, hospital and physician records, DNA diagnostic lab reports, the HD research lab at the Centre for Molecular Medicine and Therapeutics (CMMT), nursing homes, The Huntington Society of Canada and HD community members. Results: The minimum prevalence of HD in BC was estimated at 12.5 - 14.9/100,000 (95% CI: 11.5-16.0) (1/8,697 – 1/6,250), the incidence, 7.2 per million/year (95% CI: 6.5-7.9), and the minimum population at risk: 1/1,064 (95% CI: 1/1,941 - 1/2,107). Conclusions: The prevalence of HD is nearly twice as high as suggested by a previous Canadian report. This study comprised the most thorough HD patient ascertainment study since the advent of direct mutation testing and may set a precedent for future prevalence studies. Incidence has remained the same since 1999 and BC is only the fourth region in the world to provide a direct estimate of the population at risk for HD. Medicine, Faculty of Medical Genetics, Department of Graduate 2012-10-02T16:37:58Z 2012-10-02T16:37:58Z 2012 2012-11 Text Thesis/Dissertation http://hdl.handle.net/2429/43319 eng Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ University of British Columbia
collection NDLTD
language English
sources NDLTD
description Introduction: Global prevalence estimates for Huntington Disease (HD) vary widely, and those cited for Canada are outdated and not specific to British Columbia (BC). The most recent incidence calculation was performed in BC and includes diagnoses only up to the year 1999. Reports on the population at risk in Canada are based on theories and estimates that do not pertain to any particular population. Despite the presence of an extensive laboratory and clinical research hub in this province, a comprehensive epidemiological study of the prevalence, incidence and population at risk for HD has never been assessed. As such, the specific objectives of this study were to: 1) Calculate the minimum prevalence of HD in BC on April 1, 2012; 2) Calculate the incidence of HD in BC from January 1, 2001- December 31, 2011; and 3) Calculate the minimum population at risk for HD in BC on April 1, 2012. Methods: A comprehensive province-wide assessment of the HD patient population and the population at risk was conducted using multiple sources of ascertainment including: UBC HD clinic records, hospital and physician records, DNA diagnostic lab reports, the HD research lab at the Centre for Molecular Medicine and Therapeutics (CMMT), nursing homes, The Huntington Society of Canada and HD community members. Results: The minimum prevalence of HD in BC was estimated at 12.5 - 14.9/100,000 (95% CI: 11.5-16.0) (1/8,697 – 1/6,250), the incidence, 7.2 per million/year (95% CI: 6.5-7.9), and the minimum population at risk: 1/1,064 (95% CI: 1/1,941 - 1/2,107). Conclusions: The prevalence of HD is nearly twice as high as suggested by a previous Canadian report. This study comprised the most thorough HD patient ascertainment study since the advent of direct mutation testing and may set a precedent for future prevalence studies. Incidence has remained the same since 1999 and BC is only the fourth region in the world to provide a direct estimate of the population at risk for HD. === Medicine, Faculty of === Medical Genetics, Department of === Graduate
author Fisher, Emily Rachel
spellingShingle Fisher, Emily Rachel
The epidemiology of Huntington disease in British Columbia
author_facet Fisher, Emily Rachel
author_sort Fisher, Emily Rachel
title The epidemiology of Huntington disease in British Columbia
title_short The epidemiology of Huntington disease in British Columbia
title_full The epidemiology of Huntington disease in British Columbia
title_fullStr The epidemiology of Huntington disease in British Columbia
title_full_unstemmed The epidemiology of Huntington disease in British Columbia
title_sort epidemiology of huntington disease in british columbia
publisher University of British Columbia
publishDate 2012
url http://hdl.handle.net/2429/43319
work_keys_str_mv AT fisheremilyrachel theepidemiologyofhuntingtondiseaseinbritishcolumbia
AT fisheremilyrachel epidemiologyofhuntingtondiseaseinbritishcolumbia
_version_ 1718583530770923520